Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report findings.
Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report findings:
- Global Peptide Therapeutics Market Opportunity > USD 75 billion by 2028
- Global Peptide Therapeutics Clinical Trials Insight by Company, Indication & Phase
- Peptide Therapeutics in Clinical trials: > 800 Drugs
- Peptide Therapeutics Commercially Available In Market: > 200 Drugs
- Global Peptide Therapeutics Clinical Trials Insight By Peptide Type: Glucagon-like Peptides, Cyclic Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioid, Depsipeptides, Neuropeptides, Natriuretic, Bicyclic Peptides
Download Report:
https://www.pnspharma.com/reports/global-peptide-therapeutics-market-clinical-trials-insight-2028
Peptides constitute a special class of molecularly regulated, but biochemically and therapeutically distinct, pharmaceutical compounds. During the past decade, peptides have gained a wide range of applications in medicine and biotechnology. Since the introduction of insulin almost a century ago, more than 200 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain. This number is expected to grow significantly, with approximately 700 peptide drugs peptides currently in clinical trials in preclinical development.
Research studies are also expanding the role of peptide therapeutics for the management of orphan diseases. Recently, US FDA announced clearance of an Investigational New Drug (IND) application for a Phase 2 clinical trial of RLS-0071 in neonates with hypoxic-ischemic encephalopathy (HIE). RLS-0071 developed by ReAlta Life Science is dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy and other rare diseases. RLS-0071 is a 15 amino acid peptide that inhibits both humoral inflammation by blocking classical pathway complement activation and cellular inflammation by blocking the neutrophil effectors myeloperoxidase (MPO) and neutrophil extracellular traps (NETs). The widespread application of peptide therapeutics in wide range of diseases is also propelling the growth of market during the forecast period.
The majority of therapeutic peptides are administered by the parenteral route because of insufficient absorption from the gastrointestinal tract. Peptide drugs are usually indicated for chronic conditions, and the use of injections on a daily basis during long-term treatment has significant drawbacks. The main reasons for the low oral bioavailability of peptide drugs are pre-systemic enzymatic degradation and poor penetration of the intestinal mucosa. Also, this therapeutics tends to have a high molecular weight, low lipophilicity, and charged functional groups that hamper their absorption. These characteristics lead to the low bioavailability of most orally administered peptides and short half-lives. However, researchers are currently conducting several ongoing clinical trials to develop enhance peptide therapeutics which can overcome these limitations.
The global peptide therapeutics market is both competitive along with being fragmented on account of the presence of several international and also domestic industry players. Such industry players have utilized an assorted innovative strategies for being at the top along with sufficing to the burgeoning requirement of the esteemed clients including geographic expansions, collaborations, joint ventures, new product launches, partnerships, contracts, and much more. For instance, Bicycle Therapeutics has entered into strategic collaboration with Genentech to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Further, Fusion Pharmaceuticals also enter into collaboration with Pepscan to discover, novel, peptide-based radiopharmaceuticals for the management of solid tumors.
As per our analysis, the global peptide therapeutics market is expected to surpass US$ 75 Billion by 2028. The growing prevalence of acute and chronic diseases, along with the rising access to medical facilities, represents one of the leading factors positively influencing the demand for peptides to develop innovative therapies. Furthermore, the emerging trend of personalized and targeted treatments is catalyzing the demand for multifunctional peptide-based materials. This, along with the rising funding to develop novel peptide therapeutics for treating autoimmune and inflammatory diseases, is projected to create a positive market outlook.
The report provides detailed review of the overall market landscape of peptide-based therapies, including information on their current phase of development (marketed, clinical, preclinical and discovery), type of peptide, route of administration, and key therapeutic area. The report also gives insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules. This report forecasts revenue growth at global and regional levels and provides an analysis of the latest trends and opportunities.
Contact:
Rajesh Arora
Senior Analyst
PNS Pharma